What is transarterial chemoembolization?

Transarterial chemoembolization (TACE) remains the established standard-of-care locoregional therapy for patients with intermediate-stage hepatocellular carcinoma (HCC) and select early-stage lesions unsuitable for curative resection, ablation, or transplantation.^[1] The procedure delivers concentrated cytotoxic chemotherapy directly into the hepatic arterial supply feeding hepatic tumors, followed by embolic occlusion of the target vessels. This dual mechanism—high local drug concentration combined with ischemic tumor necrosis—exploits the predominantly arterial blood supply of HCC while relatively sparing normal hepatic parenchyma, which derives 70-80% of its perfusion from the portal venous system.^[2]

Two primary techniques dominate contemporary practice. Conventional TACE (cTACE) combines lipiodol with a chemotherapeutic agent—typically doxorubicin or epirubicin—followed by embolic particles such as gelatin sponge or polyvinyl alcohol (PVA). Drug-eluting bead TACE (DEB-TACE) uses calibrated microspheres pre-loaded with doxorubicin that slowly release the drug over 7-14 days, potentially reducing systemic drug exposure and standardizing the embolic effect.^[3] Recent meta-analyses demonstrate that DEB-TACE achieves superior objective response rates and overall survival compared to cTACE, with comparable safety profiles.^[4]

The therapeutic rationale for TACE is grounded in the unique vascular biology of HCC. Unlike normal hepatocytes, hepatocellular carcinoma cells derive nearly 100% of their blood supply from the hepatic artery. By superselectively catheterizing tumor-feeding arterial branches, interventional radiologists achieve intra-tumoral drug concentrations up to 40 times higher than systemic administration, while embolic-induced ischemia triggers secondary tumor cell death.^[5]

Patient selection and indications

The Barcelona Clinic Liver Cancer (BCLC) staging system stratifies patients who benefit most from transarterial chemoembolization. Current EASL and AASLD guidelines recommend TACE for BCLC stage B (intermediate-stage) HCC—defined as multinodular disease, preserved performance status (ECOG 0-1), and relatively maintained hepatic function (Child-Pugh class A or B7).^[7] TACE also serves as first-line therapy for early-stage HCC (BCLC 0-A) when surgical resection, percutaneous ablation, or liver transplantation are contraindicated due to anatomic location, inadequate future liver remnant, or significant patient comorbidities.

Beyond palliation, TACE functions as a bridge to liver transplantation by downstaging tumor burden to within Milan criteria, and as a definitive treatment for recurrent HCC following prior curative therapy.^[8] The BRIDGE study, a large multinational cohort, demonstrated that TACE is the most commonly applied treatment modality for HCC across diverse geographic regions and healthcare systems, underscoring its central role in multidisciplinary hepatobiliary oncology.^[9]

Patient selection demands multidisciplinary evaluation incorporating hepatology, surgical oncology, transplant surgery, and interventional radiology input. The HAP (Hepatic Arterial Infusion Pump) score and ALBI (Albumin-Bilirubin) grade provide objective metrics for predicting treatment tolerance and survival. Tumor burden, hepatic functional reserve, extrahepatic disease status, and portal vein patency collectively determine candidacy.^[10]

Selection criteria for optimal outcomes

Ideal candidates for transarterial chemoembolization exhibit Child-Pugh class A cirrhosis, ECOG performance status 0-1, absence of main portal vein thrombosis, and no extrahepatic metastatic disease. Patients with Child-Pugh B7 may be treated selectively, though they require modified protocols and heightened surveillance for hepatic decompensation. The STATE score and ABCR score (Albumin-Bilirubin, Child-Pugh, and Response) further refine prognostication and retreatment decisions.^[11]

Pre-procedural workup and preparation

Comprehensive pre-procedural assessment minimizes complications and optimizes outcomes. Mandatory laboratory evaluation includes complete blood count, comprehensive metabolic panel, coagulation studies, and serum alpha-fetoprotein (AFP). Cross-sectional imaging with multiphasic CT or MRI within four weeks confirms tumor burden, vascular anatomy, portal vein patency, and absence of extrahepatic disease.^[12]

Hepatic functional reserve determines procedural safety. Child-Pugh class A and selected B7 patients tolerate TACE well; Child-Pugh C carries prohibitive risk of liver failure. The ALBI grade and MELD score provide additional objective risk stratification beyond the Child-Pugh system. Prophylactic antibiotics—typically a third-generation cephalosporin with metronidazole—are administered when biliary-enteric anastomosis, prior biliary intervention, or diabetes increase infectious risk.^[13]

Patients should remain nil per os (NPO) for six hours before the procedure. Intravenous hydration beginning pre-procedure reduces contrast-induced nephropathy risk, particularly in patients with baseline renal dysfunction. Anti-emetic prophylaxis with 5-HT3 receptor antagonists and peri-procedural corticosteroids attenuate post-embolization syndrome severity and duration.^[14] Pre-procedure pain assessment and multimodal analgesia planning improve patient tolerance and satisfaction.

Vascular access and catheterization technique

Arterial access is obtained via the common femoral artery (CFA) using a 4-5 French vascular sheath under local anesthesia and moderate sedation. Transradial access represents an increasingly utilized alternative that reduces patient discomfort, shortens ambulation time, and decreases radiation exposure to the operator, though femoral access remains standard for complex catheterization requiring reverse-curve catheters.^[16]

Diagnostic angiography of the celiac trunk and superior mesenteric artery (SMA) identifies variant hepatic arterial anatomy. The replaced right hepatic artery originating from the SMA occurs in approximately 10-15% of patients, while the replaced left hepatic artery from the left gastric artery occurs in 5-10%. Recognition of these variants is mandatory to ensure complete tumor coverage and avoid nontarget embolization.^[17]

Selective catheterization progresses from the common hepatic artery to lobar, segmental, and ultimately subsegmental branches supplying the tumor. Superselective catheterization—defined as cannulation of segmental or subsegmental feeders—reduces hepatic toxicity and improves tumor response by concentrating therapy within the target lesion. Microcatheters (2.4-2.8 French) advanced over 0.014-0.018-inch microwires enable distal navigation through tortuous vessels. Cone-beam CT (CBCT) performed during the procedure confirms tumor-feeding arteries, identifies extrahepatic collateral supply, and maps the perfusion territory to prevent nontarget embolization.^[18]

Protection of extrahepatic branches

Before embolization, operators must identify and protect extrahepatic arteries at risk of nontarget occlusion. The cystic artery, gastroduodenal artery (GDA), right gastric artery, and falciform artery require careful evaluation. When these vessels arise proximally to the target territory or demonstrate dangerous anastomoses, coil embolization or temporary balloon occlusion may be employed to prevent gastrointestinal complications.^[19]

Imaging parameters and contrast protocol

Digital subtraction angiography (DSA) requires frame rates of 3-6 frames per second with 15-30 second acquisition runs to characterize arterial inflow, tumor blush, and portal vein perfusion. Roadmap fluoroscopy facilitates microcatheter navigation through tortuous vessels and reduces procedural radiation dose.^[20]

Non-ionic iodinated contrast (Visipaque 320 or Omnipaque 350) is used for diagnostic injections. Selective hepatic arteriography employs 5-10 mL per injection at 3-5 mL/s. CBCT for tumor perfusion mapping requires 8-12 mL injected at 2-3 mL/s through the microcatheter positioned in the feeding artery. Post-procedure flat-panel CT immediately following embolization documents lipiodol retention within the tumor and detects acute complications such as nontarget deposition or arterial dissection.

Total contrast volume should be minimized in patients with chronic kidney disease; CO2 angiography serves as an effective alternative for diagnostic runs in select cases. Operators should monitor cumulative contrast load, particularly when performing bilateral lobar treatments or combined diagnostic and therapeutic injections.^[21]

Chemoembolization agents and embolic selection

cTACE employs a lipiodol-chemotherapeutic emulsion created by mixing iodized oil with doxorubicin (30-75 mg/m2, maximum 150 mg) or epirubicin. The lipiodol serves as both a drug carrier and a radiopaque embolic agent, remaining trapped within the tumor's sinusoidal spaces due to absent Kupffer cell function and abnormal tumor neovasculature. Embolization is completed using absorbable gelatin sponge (Gelfoam) slurry or PVA particles (300-500 um) until near-stasis of arterial flow.^[22]

DEB-TACE uses calibrated microspheres (DC Beads, HepaSphere, or CalliSpheres, typically 100-300 um or 300-500 um) pre-loaded with doxorubicin (50-150 mg depending on tumor burden). The beads provide sustained drug release over 7-14 days and a standardized embolic effect independent of operator mixing technique. A 2025 meta-analysis of 4,367 patients demonstrated that DEB-TACE achieved significantly higher complete response rates, longer overall survival (+3.54 months), and superior progression-free survival (+3.07 months) compared to cTACE, with comparable complication rates.^[4]

Agent selection depends on tumor size, number, vascularity, hepatic reserve, and institutional experience. cTACE remains widely used for its cost-effectiveness and long track record, while DEB-TACE offers pharmacokinetic advantages for patients with larger tumor burden or those requiring repeated treatments.^[23]

Step-by-step procedural protocol

The following standardized protocol ensures consistent technique and optimal outcomes across operators:

1. Obtain arterial access and place vascular sheath under sterile conditions. Administer prophylactic antibiotics and anti-emetics per institutional protocol.
2. Perform aortography and selective celiac/SMA angiography to map arterial anatomy and identify variant vessels.
3. Advance diagnostic catheter into the common hepatic artery and obtain selective lobar angiograms.
4. Identify and coil-embolize high-risk extrahepatic branches (gastroduodenal artery, right gastric artery, cystic artery) if they originate near the target territory or demonstrate dangerous anastomoses.
5. Advance microcatheter into the tumor-feeding artery using roadmap guidance. Confirm position with gentle contrast injection.
6. Perform CBCT to confirm target vessel perfusion territory and exclude nontarget supply to bowel, gallbladder, or diaphragm.
7. For cTACE: Inject lipiodol-drug emulsion slowly under continuous fluoroscopy until the tumor is densely opacified and portal vein branches near the tumor are visualized. Follow with Gelfoam slurry or PVA particles until near-stasis.
8. For DEB-TACE: Inject drug-loaded beads suspended in non-ionic contrast-saline mixture slowly under fluoroscopy until stasis or near-stasis of arterial flow is achieved.
9. Obtain completion angiography to confirm occlusion of target vessels and absence of nontarget flow or reflux.
10. Remove catheter and achieve hemostasis at access site using manual compression or vascular closure device.

Post-embolization syndrome management

Post-embolization syndrome (PES) represents the most common adverse event following transarterial chemoembolization, occurring in up to 80% of patients.^[24] The constellation of fever, right upper quadrant pain, nausea, vomiting, and malaise reflects tumor ischemia, inflammatory cytokine release, and transient hepatic dysfunction. Symptoms typically peak at 24-48 hours and resolve within 3-7 days, though severe cases may persist for one week.

Evidence-based management includes prophylactic corticosteroids (dexamethasone 8-12 mg IV) and 5-HT3 receptor antagonists (ondansetron 4-8 mg IV) administered peri-procedurally.^[25] Patient-controlled analgesia (PCA) with opioids or scheduled NSAIDs (parecoxib) effectively controls pain, though non-steroidal anti-inflammatory drugs require caution in patients with cirrhosis due to renal dysfunction and bleeding risk. Aggressive intravenous hydration, anti-emetics, and antipyretics support recovery. Most patients require overnight observation; same-day discharge is feasible only in highly selected cases with robust social support.

PES is self-limiting; however, persistent fever beyond one week, rising white blood cell count, or progressive right upper quadrant pain warrants immediate cross-sectional imaging to exclude hepatic abscess, gallbladder necrosis, or tumor rupture. Liver abscess occurs in 0.1-4.5% of procedures and carries mortality of 11-13% if untreated, necessitating percutaneous drainage and targeted antibiotics.^[15]

Expected outcomes and response assessment

Treatment response is evaluated using modified RECIST (mRECIST) criteria on multiphasic CT or MRI performed 4-6 weeks post-TACE.^[26] Unlike conventional RECIST 1.1, mRECIST measures only the viable (arterially enhancing) component of target lesions, excluding areas of necrosis or lipiodol retention. Complete response (CR) requires disappearance of all intralesional arterial enhancement. Partial response (PR) is defined as >=30% decrease in the sum of diameters of viable target lesions. Objective response rates (CR + PR) range from 50-60% following conventional TACE and are significantly higher with DEB-TACE.^[27]

Contemporary randomized trials report median overall survival of 26-30 months for intermediate-stage HCC treated with TACE, with progression-free survival of approximately 8 months.^[6] The ART score (Assessment for Retreatment with TACE) and ABCR score predict survival and guide decisions regarding repeat TACE versus transition to systemic therapy. Patients achieving objective response by mRECIST demonstrate significantly prolonged survival compared to those with stable or progressive disease.^[28]

Beyond imaging, serum AFP response provides complementary prognostic information. A >=50% decline in AFP at 4-6 weeks post-TACE correlates with improved overall survival and may identify responders earlier than radiographic assessment. Multiparametric response assessment incorporating imaging, biomarkers, and clinical status optimizes treatment sequencing decisions.^[29]

Complications and risk mitigation

Significant complications occur in approximately 5-10% of TACE procedures.^[30] Hepatic decompensation and liver failure represent the most serious adverse events, particularly in patients with marginal reserve (Child-Pugh B), excessive embolization volume, or unrecognized portal vein thrombosis. Bile duct injury, gallbladder necrosis, and permanent biliary strictures arise from nontarget embolization of the cystic or peribiliary arterial plexus. Careful microcatheter positioning and embolization to near-stasis rather than complete occlusion mitigate these risks.

Hepatic abscess develops in 0.1-4.5% of cases, with mortality reaching 11-13% if untreated.^[15] Risk factors include prior biliary surgery, biliary-enteric anastomosis, diabetes mellitus, and excessive embolization of the left lobe where the biliary tree is more vulnerable. Prophylactic broad-spectrum antibiotics covering enteric organisms and meticulous sterile technique are essential preventive measures. Tumor rupture, cholecystitis, arterial dissection, and nontarget embolization to the stomach, duodenum, or pancreas occur rarely but require prompt recognition and management.

Contrast-induced nephropathy is mitigated by pre-procedure hydration, minimization of contrast volume, and avoidance of nephrotoxic medications. Post-procedure acute kidney injury is uncommon but mandates careful medication review in patients with pre-existing renal dysfunction. Access site complications—hematoma, pseudoaneurysm, arteriovenous fistula—are minimized by ultrasound-guided puncture and appropriate closure technique.^[31]

Follow-up imaging and surveillance

Cross-sectional imaging with multiphasic CT or MRI is obtained at 4-6 weeks following the initial TACE and 6-10 weeks after subsequent sessions.^[33] MRI with hepatobiliary-specific contrast (gadoxetic acid/Eovist) offers superior detection of residual viable tumor compared to CT, particularly in the setting of dense lipiodol retention that may mask enhancement on CT. The European Conference on Interventional Oncology and the European Society of Oncologic Imaging recommend MRI as the first-line modality, with CT as an acceptable alternative.

Surveillance continues every 2-3 months for the first two years, with serum AFP measurement at each visit. On-demand TACE—administered only when imaging demonstrates viable tumor without fulfilling stopping criteria—reduces hepatic toxicity and improves quality of life compared to fixed-schedule regimens.^[34] TACE refractoriness, defined by the Japan Society of Hepatology-Liver Cancer Study Group of Japan (JSH-LCSGJ) criteria as two consecutive ineffective treatments (progressive disease or stable disease without objective response) or unacceptable hepatic deterioration, mandates transition to systemic therapy.^[35]

When classification of tumor response is needed, mRECIST criteria are preferred over RECIST 1.1 for locoregional therapies. For atypical HCC lesions with heterogeneous or infiltrative growth patterns, RECIST 1.1 may provide more reproducible measurements.^[26]

Contraindications and alternative therapies

Absolute contraindications to transarterial chemoembolization include Child-Pugh C cirrhosis with MELD >18, main portal vein thrombosis without collateral circulation, ECOG performance status >2, active uncontrolled infection, and uncorrectable coagulopathy (INR >1.8 despite vitamin K, platelets <50,000/uL).^[36] Relative contraindications include total bilirubin >3 mg/dL, significant arterioportal shunting, tumor burden exceeding 50% of liver volume, and extrahepatic disease limited to the lungs where TACE may still control intrahepatic burden.

For patients with portal vein tumor thrombosis (PVTT), TACE remains feasible in Child-Pugh A patients with segmental thrombus and adequate collateral flow, though hepatic artery infusion chemotherapy (HAIC) or transarterial radioembolization (TARE) may offer superior outcomes for main PVTT.^[32] Systemic therapy with atezolizumab plus bevacizumab has become the first-line standard for advanced HCC (BCLC C), demonstrating superior overall survival compared to sorafenib.^[37] Stereotactic body radiotherapy (SBRT) provides a non-invasive alternative for patients with contraindications to arterial intervention, while percutaneous ablation (radiofrequency or microwave) remains preferred for small, accessible lesions <=3 cm.

The integration of TACE with systemic therapy represents an evolving paradigm. The EMERALD-1 and LEAP-012 trials demonstrated significant improvements in progression-free survival when TACE was combined with durvalumab plus bevacizumab or lenvatinib plus pembrolizumab, respectively, establishing immunotherapy-chemoembolization combinations as the emerging standard for select intermediate-stage patients.^[38]

Conclusion

Transarterial chemoembolization remains the cornerstone of locoregional therapy for intermediate-stage hepatocellular carcinoma, with established survival benefit and acceptable safety when applied to appropriately selected patients. Mastery of patient selection, superselective catheterization technique, and evidence-based management of post-embolization syndrome distinguishes high-volume centers and directly impacts oncologic outcomes.

The evolution from conventional lipiodol-based TACE to drug-eluting bead platforms has improved objective response rates and standardised drug delivery, while emerging integration with systemic immunotherapy repositions TACE as a dynamic therapeutic modality rather than merely a palliative intervention. For radiologists, radiographers, and hospital administrators, ensuring institutional protocols reflect contemporary guideline recommendations, rigorous patient triage, and standardized follow-up surveillance is essential to maximize clinical outcomes and resource efficiency.